Assessment of cancer procoagulant activity in patients with multiple myeloma

Krzysztof Chojnowski, Jacek Treliński, Malgorzata Kamocka, Wojciech P. Mielicki

Research output: Contribution to journalArticle

2 Scopus citations


Pathomechanism of coagulation disorders in multiple myeloma (MM) patients is a complex one but most frequently connected with the presence of monoclonal protein. Until today the role of cancer procoagulant (CP) has not been studied in MM. In the paper CP activity in 26 patients with MM was tested. In 31% of patients elevated levels of CP activity above baseline was observed. Mean CP activity was higher in MM group than in control but without statistical significance. No major differences between mean CP activity in II and III stage of the disease MM type, and no correlation between CP activity and the concentration of monoclonal protein was seen. In none of the patients with CP activity above normal any thrombotic complications were observed.

Original languageEnglish (US)
Pages (from-to)73-79
Number of pages7
JournalActa Haematologica Polonica
Issue number1
StatePublished - Jan 1 2005
Externally publishedYes


  • Cancer procoagulant
  • Myeloma multiplex
  • Thrombosis

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Assessment of cancer procoagulant activity in patients with multiple myeloma'. Together they form a unique fingerprint.

  • Cite this